Teladoc Health (NYSE:TDOC) had its target price upped by equities researchers at SVB Leerink from $246.00 to $256.00 in a research note issued on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the health services provider’s stock. SVB Leerink’s price target would indicate a potential upside of 12.81% from the company’s previous close. SVB Leerink also issued estimates for Teladoc Health’s FY2022 earnings at $0.48 EPS.
Other analysts have also issued research reports about the stock. Citigroup initiated coverage on shares of Teladoc Health in a research note on Tuesday, July 14th. They issued a “buy” rating and a $275.00 price objective for the company. KeyCorp lifted their price target on shares of Teladoc Health from $240.00 to $245.00 and gave the company an “overweight” rating in a research note on Thursday. Cantor Fitzgerald increased their price objective on shares of Teladoc Health from $165.00 to $210.00 and gave the stock a “neutral” rating in a research report on Thursday, July 30th. Wells Fargo & Company boosted their target price on Teladoc Health from $135.00 to $175.00 in a research report on Thursday, July 30th. Finally, JPMorgan Chase & Co. raised their price objective on Teladoc Health from $240.00 to $266.00 and gave the company an “overweight” rating in a research note on Thursday, July 30th. Twelve analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $216.28.
Shares of Teladoc Health stock opened at $226.94 on Thursday. The business has a 50-day moving average price of $213.11 and a two-hundred day moving average price of $198.69. Teladoc Health has a 1-year low of $67.46 and a 1-year high of $253.00. The company has a current ratio of 11.36, a quick ratio of 11.36 and a debt-to-equity ratio of 0.73. The company has a market cap of $18.83 billion, a P/E ratio of -177.30 and a beta of 0.25.
Teladoc Health (NYSE:TDOC) last announced its earnings results on Wednesday, October 28th. The health services provider reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.10). Teladoc Health had a negative net margin of 13.22% and a negative return on equity of 9.54%. Equities research analysts forecast that Teladoc Health will post -1.4 EPS for the current fiscal year.
In related news, SVP Andrew Turitz sold 1,389 shares of Teladoc Health stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $222.46, for a total value of $308,996.94. Following the sale, the senior vice president now owns 4,732 shares of the company’s stock, valued at approximately $1,052,680.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jason N. Gorevic sold 30,000 shares of the stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $222.26, for a total value of $6,667,800.00. Following the transaction, the chief executive officer now directly owns 697,283 shares of the company’s stock, valued at $154,978,119.58. The disclosure for this sale can be found here. Insiders have sold a total of 79,698 shares of company stock worth $18,329,567 over the last quarter. Company insiders own 3.42% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Jennison Associates LLC grew its stake in shares of Teladoc Health by 705.3% during the 2nd quarter. Jennison Associates LLC now owns 3,673,947 shares of the health services provider’s stock worth $701,136,000 after acquiring an additional 3,217,743 shares during the period. First Trust Advisors LP increased its position in shares of Teladoc Health by 1,406.6% during the second quarter. First Trust Advisors LP now owns 1,001,290 shares of the health services provider’s stock valued at $191,086,000 after buying an additional 934,829 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Teladoc Health by 70.2% in the second quarter. Goldman Sachs Group Inc. now owns 936,259 shares of the health services provider’s stock worth $178,676,000 after buying an additional 386,086 shares in the last quarter. Tobam bought a new position in shares of Teladoc Health in the second quarter valued at approximately $35,072,000. Finally, Sumitomo Mitsui Trust Holdings Inc. grew its stake in Teladoc Health by 84.3% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 381,694 shares of the health services provider’s stock valued at $72,842,000 after acquiring an additional 174,585 shares in the last quarter. 87.39% of the stock is currently owned by hedge funds and other institutional investors.
Teladoc Health Company Profile
Teladoc Health, Inc provides virtual healthcare services on a business-to-business basis in the United States and internationally. It covers various clinical conditions, including non-critical, episodic care, chronic, and complicated cases like cancer and congestive heart failure, as well as offers telehealth solutions, expert medical services, behavioral health solutions, guidance and support, and platform and program services.
Recommended Story: Correction
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.